Boehringer Ingelheim has shared data on its DLL3xCD3 T-cell engager, providing pointers to the prospects of a would-be rival ...

Takeda has lifted the lid on the phase 3 win for its next-generation claudin18.2 drug, with the antibody-drug conjugate (ADC) ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

| Pathos AI has closed a $237 million series E round led by pharma giant Bristol Myers Squibb on the same day that the two ...

Roche is paying Zymeworks $55 million upfront for ZW209, bagging global rights to a trispecific designed to improve on the ...

Despite the sweeping scope of the ban covering various types of drug molecules, biopharma business development teams can ...

Merck & Co. and Moderna have shared highly anticipated phase 3 data on their cancer vaccine, revealing a primary endpoint hit ...

Quest Diagnostics is the latest life sciences company to fall victim to a cyberattack, with the company believing patient ...

Celltrion has licensed a preclinical antibody aimed at autoimmune conditions from Maryland-based biotech Kaigene in a deal ...

Georgiamune, an immunology-focused biotech out of Maryland, has licensed a preclinical cancer drug candidate to Menarini ...

Japan's Astellas Pharma has tapped Boston computational discovery company AI Proteins in a drug discovery deal potentially ...

Reverse mergers have returned with a bang. More biotechs have taken this back door to the public markets so far in 2026 than ...